West Pharmaceutical Services Inc (WST) · Jul 23, 2026 · Earnings

Large Q2 beat with guidance raised, despite cyber-hit margins

Beat — Adjusted EPS $2.37 vs ~$2.08 consensus; revenue $872.3M vs ~$839.8M

Large Q2 beat with guidance raised, despite cyber-hit margins

The quarter cleared both the internal and published bar by a wide margin. Adjusted EPS was $2.37 versus a published consensus of roughly $2.08, while revenue was $872.3 million versus roughly $839.8 million expected. The filing also says results exceeded management’s expectations, but the more important point is that the gap was visible in both earnings and sales—not just a favorable mix or tax benefit. (Financial Highlights; Income Statement)

MetricQ2 2026Q2 2025Versus expectation
Revenue$872.3M$766.5M~$839.8M consensus
Organic revenue growth12.7%—Q2 guide: 7.0%-9.6%
Adjusted diluted EPS$2.37$1.84~$2.08 consensus
Adjusted operating margin22.6%20.3%+230 bps YoY
Gross margin37.7%35.7%+200 bps YoY
West Vantage organic growth0.8%—Margin impacted by cyber incident

The growth engine was substantially stronger than the headline average suggests. Proprietary Products, representing 83% of sales, grew 15.5% organically, led by HVP Components at 18.4% and HVP Delivery Devices at 29.2%. Biologics grew 29.2% organically and accounted for 43% of company revenue, while GLP-1-related revenue represented 18% of sales. (Segment results — Proprietary Products; Revenue by Product Category; Revenue by Market Group)

Management converted the beat into a meaningful outlook upgrade. Full-year revenue guidance moved to $3.345-$3.380 billion from the prior $3.295-$3.350 billion range, and adjusted EPS guidance rose to $8.85-$9.05 from $8.40-$8.75. The new Q3 EPS guide of $2.14-$2.24 also sits modestly above the roughly $2.12 published expectation, while Q3 revenue guidance of $820-$835 million is above the roughly $814.7 million consensus. (2026 / Q3 Guidance; Reconciliation of Adjusted-Diluted EPS Guidance)

The main offset is execution risk in the lower-growth segment and weaker cash conversion. West Vantage grew only 0.8% organically, and its operating margin fell to 8.6% from 12.1% as the May 2026 cyber incident weighed on gross margin. First-half operating cash flow fell to $213.9 million from $306.5 million, while free cash flow declined to $128.0 million from $160.0 million, despite lower capital spending. The company also spent $454.3 million on share repurchases, leaving cash at $435.8 million versus $791.3 million at year-end. (Segment results — West Vantage; Cash Flow statement; Balance Sheet)

Net read: a genuine earnings beat with upgraded expectations, not merely a strong-looking quarter. The magnitude of the sales and EPS upside, broad strength across biologics and HVP products, and higher full-year targets outweigh the cyber-related margin pressure and weaker first-half cash generation. The result was partly known in direction because Q1 had already established strong momentum and raised guidance, but this filing materially increased the size of the expected earnings path. (Q2 Financial Highlights; 2026 Guidance)

What to watch next

Q3 report, late October

Original filing on SEC EDGAR

More West Pharmaceutical Services Inc news

Large Q2 beat with guidance raised, despite cyber-hit margins | WST Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.